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Abstract
Backgroud—Side effects of prescribed and non-prescribed psychostimulant use are 
understudied.
Objectives—The study examined side effects of prescribed and non-prescribed psychostimulant 
use in a college sample with attention to possible gender differences.
Methods—2716 undergraduates (1448 male) between the ages of 17 and 57 years (M=19.43 
years, SD= 1.7 years) completed an online survey that included questions about the subjective side 
effects of prescribed and non-prescribed psychostimulant use.
Results—Results suggested that prescribed users more frequently reported side effects, 
compared to non-prescribed users. For prescribed users, females more frequently reported 
appetite, somatic, and anxiety-related side effects compared to males. For non-prescribed users, 
while females reported more somatic and anxiety-related side effects, males more frequently 
reported loss of sex drive and sweating as side effects.
Conclusions/Importance—These findings suggest prescribed users of psychostimulants more 
frequently report side effects with prominent gender differences in line with gender roles.
Keywords
Psychostimulants; side effects; non-prescribed use; gender differences
Prescribed and non-prescribed use of psychostimulant medications has been increasing 
among young adults on college campuses with rates as high as a third. For example, 
DeSantis, Webb, and Noar (2008) reported that 34% of their college-student sample had 
used Adderall and other Attention Deficit/Hyperactivity Disorder (ADHD) medications 
nonmedically for enhanced academic performance and for recreational use. Similarly, 
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Advokat, Guidry, and Martino (2008) revealed that 43% of the 1,387 undergraduate students 
in their study had accessed ADHD stimulant medications without a prescription. A recent 
meta-analysis suggests rates of psychostimulant misuse on college campuses to be 
approximately 17% (Benson, Flory, Humphreys, & Lee, 2015). This meta-analysis further 
found several psychological and social variables associated with misuse, including ADHD 
symptoms, alcohol and marijuana use, Greek organization membership, and academic 
performance (Benson et al., 2015). While reasons why college students use non-prescribed 
psychostimulants require further investigation, Teter et al. (2005) found the three most 
reported motives for non-prescribed use were to help with concentration, increase alertness, 
and to provide a high. This appears to be an important and fairly prevalent issue in college 
samples.
Despite the growing prevalence of use of psychostimulants for treatment and for non-
prescribed use, differences in how the side effects of these medications are experienced for 
prescribed and non-prescribed users are understudied. Rapport and Moffitt (2002) examined 
side effects of prescribed methylphenidate use in children with ADHD and found that these 
side effects included weight loss, reductions in height velocity, elevated heart rate, increased 
blood pressure, reduced appetite, sleep disturbance, headaches, dizziness, and stomachaches, 
grouped into three classes: height/weight, cardiovascular, and somatic complaints. Morton 
and Stockton (2000) reported that, although side effects of methylphenidate are generally 
well tolerated, nonprescription use of methylphenidate produces effects that are similar to 
the effects of cocaine, which can be dangerous and even deadly.
While basic side effects of psychostimulants have been examined and differences in 
prescribed and non-prescribed use have been suggested in children (Morton & Stockton, 
2000), adult populations are understudied. Particularly, side effects of nonprescription 
psychostimulant use have not been examined, despite the possibility that such side effects 
may well differ from those prescribed psychostimulants under physician care. The lack of 
such information is particularly alarming given the growing trend for nonprescription use of 
psychostimulants on college campuses among young adults. In addition, there has been 
some indication of gender differences in drug responses (Anderson, 2008; Franconi et al., 
2007; Haack et al., 2009; Tran et al., 1998); yet, the possibility that there may be gender 
differences in side effects to psychostimulants has never been studied, to our knowledge. 
Research suggests adverse drug reactions are higher in females than males, which might be 
due to sex differences in weight, metabolism, and body fat (Anderson, 2008), as well as 
socialization processes leading to differences in acknowledgement and reporting of 
discomfort, and gender differences in the prevalence of anxiety and depression (Barsky, 
Peekna, & Borus, 2001). Therefore, the goal of the present study was to address these gaps 
in the literature by examining differences in reported side effects of prescribed and non-
prescribed psychostimulant use in a college sample with attention to possible gender 
differences.
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Method
Participants
Participants were 2716 undergraduates (1448 male) between the ages of 17 and 57 years 
(M=19.43 years, SD= 1.7 years) at a large Southern university in the United States enrolled 
in an introductory course. The majority of participants were Caucasian (83.5%), and most 
were freshman (45.6%) or sophomores (29.3%; Table 1). Three hundred ten (11.4%) 
participants reported an ADHD diagnosis, and 197 (7.3%) reported taking prescribed 
psychostimulant medication to treat ADHD (15% of those diagnosed). Of those taking 
prescribed stimulants, the majority reported taking lisdexamfetamine (Vyvanse, 46%) or 
amphetamine and dextroamphetamine (Adderall, 43%). Eight hundred twenty-six (30.4%) 
of the participants had taken non-prescribed psychostimulants, which did not include any of 
the individuals who had taken prescribed psychostimulants. Of those taking non-prescribed 
stimulants, the majority reported taking amphetamine/dextroamphetamine (Adderall, 85%) 
followed by lisdexamfetamine (Vyvanse, 49%), with the remainder of non-prescribed users 
taking methylphenidate (Concerta, 17%; Ritalin, 16%; Methylin, 1%), dexmethylphenidate 
(Focalin, 4%), dextroamphetamine (Dexedrine, 1%), or atomoxetine (Starttera, 1%). Seven 
percent of non-prescribed users reported they did not know the name of the stimulant they 
have taken. All participants completed informed consent, in conformity with local IRB, 
NIH, and APA ethical guidelines.
Measures
The DeSantis et al. (2008) online survey was utilized to examine subjective side effects of 
nonprescription use of psychostimulants in undergraduate students. Relevant to our study, 
participants were asked “Have you ever taken prescribed medication for ADHD?” 
Participants were also asked “Have you ever taken a non-prescribed medication for 
ADHD?” For each question, participants were asked to respond with a yes or no. Following 
each of these questions, they were asked “How often have you experienced the following 
side effect from your use of ADHD medication?” Side effects queried included: Loss of sex 
drive; Loss of appetite; Depression; Dry mouth; Diarrhea; Dizziness; Headaches; Heartburn; 
Irritability; Nausea; Insomnia; Sweating: Increased heart rate; Nervousness; and Paranoia. 
Participants rated their experience of each side effect on a five-point Likert-type scale, 
ranging from 1 (Never) to 5 (Always).
Results
Differences in side effects for prescribed vs. non-prescribed users
Loss of appetite, insomnia, and rapid heart rate were the most commonly reported side 
effects of prescribed and non-prescribed psychostimulant use (Table 2). T-tests indicated that 
there were significant differences in self-reported side effects between prescribed and non-
prescribed users in loss of sex drive (t[1010] = 3.31, p = .001), depression (t[1010] = 9.80, p 
< .001), dry mouth (t[1010] = 2.09, p < .05), diarrhea (t[1005] = 3.99, p < .001), dizziness 
(t[1011] = 4.68, p < .001), headaches (t[1008] = 4.84, p < .001), heart burn (t[1007] = 4.92, 
p < .001), irritability (t[1011] = 8.16, p < .001), nausea (t[1007] = 2.21, p < .001), sweating 
(t[1011] = 2.57, p < .05), nervousness (t[1010] = 5.52, p < .001), and paranoia rate (t[1011] 
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= 4.24, p < .001). Of these symptoms, prescribed users reported these side effects more 
frequently in all instances.
Gender differences in side effects of psychostimulants for prescribed users
T-test indicated that there were significant gender differences in loss of appetite (t[192] = 
−2.40, p < .05), dizziness (t[192] = −2.40, p < .05), nausea (t[191] = −2.44, p < .05), 
nervousness (t[191] = −2.06, p < .05), and headaches (t[191] = −4.43, p < .01; Table 3) for 
prescribed users with females reporting experiencing these side effects more frequently than 
males.
Gender differences in side effects of psychostimulants for non-prescribed users
T-tests indicated that there were significant gender differences in side effects in nausea 
(t[814] = −2.49, p < .05), insomnia (t[818] = −2.13, p < .05), sweating (t[817] = 2.33, p < .
05), paranoia (t[817] = −2.05, p < .05), loss of sex drive (t[817] = 5.01, p < .001), dizziness 
(t[817] = −3.25, p = .001), headaches (t[815] = −3.48, p = .001), and nervousness (t[817] = 
−3.82, p < .001; Table 4) for non-prescribed users. The side effects of nausea, insomnia, 
paranoia, dizziness, headaches, and nervousness were more commonly reported by females 
compared to males, while loss of sex drive and sweating were more commonly reported by 
males, compared to females.
Discussion
Study results suggested that prescribed users more frequently reported side effects, 
compared to non-prescribed users. For prescribed users, females more frequently reported 
appetite, somatic, and anxiety-related side effects compared to males. However, for non-
prescribed users, while females reported more somatic and anxiety-related side effects, 
males more frequently reported loss of sex drive and sweating as side effects.
Counter to our hypotheses, prescribed users more frequently reported side effects than non-
prescribed users. Although prior work suggested that non-prescribed users might experience 
more severe side effects (Morton & Stockton, 2000), young adults prescribed 
psychostimulants for ADHD reported more severe side effects in our sample. One possible 
explanation for this is that prescribed users might feel like they have less control or choice in 
the matter of their psychostimulant use, leading them to perceive side effects as unwanted, 
while non-prescribed users- who are using because they choose to do so- may perceive any 
side effects as wanted consequences of using the drug (e.g., loss of appetite in order to lose 
weight). In fact, recent research suggests that young adults are able to report side effects 
when they adequately remember them or have sufficient experience with the side effects 
(Friedman, McGillivary, Murayama, & Castel, 2015); therefore, prescribed users may have 
more experience with side effects. Further, since the three most common motives college 
students report for using non-prescribed psychostimulants are to help with concentration, 
increase alertness, and provide a high (Teter et al., 2005) and those who report non-
prescribed psychostimulant use also report higher rates of alcohol use and other drugs 
(Benson et al., 2015; Teter et al., 2005), it is possible that non-prescribed users do not 
remember the side effects, or attribute the side effects to alcohol or other drugs. Due to this 
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study’s use of a convenience sample, it is possible and likely that dosage, based on body 
weight and optimal therapeutic dosage, differed between prescribed and non-prescribed 
users and accounts for the higher reported side effects of prescribed users. Lastly, prescribed 
users likely take psychostimulants more regularly than non-prescribed users. As a result, 
prescribed users may be more likely to experience side effects with frequency. It should be 
noted that these possibilities are speculative, and future research should more critically 
examine these competing explanations. However, this information sheds light on why 
psychostimulants may be exceptionally prone to abuse on college campus, as their non-
prescribed use is perceived to confer benefits without much additional cost via side effects.
This study found that females were more likely to report appetite, somatic, and anxiety-
related side effects for both prescribed and non-prescribed use, compared to males. This 
finding may be viewed as in line with gender roles and societal norms such that females 
might be more likely to endorse any and all side effects, compared to males, since it is 
viewed as more normative for females to complain or admit to weakness, compared to males 
who are supposed to be more stoic (DeSantis, 2007). Alternatively, it is possible that females 
may actually experience more side effects compared to males since they metabolize drugs 
more slowly (Anderson, 2008; Franconi et al., 2007). Interestingly, among non-prescribed 
users, males reported side effects related to sex drive and sweating, results that are in line 
with gender roles and stereotypes which suggest males are more sensitive to side effects 
affecting their performance and competition status (Nayak et al., 2000; Robinson et al., 
2004; Vierhaus, Lohaus, & Schmitz, 2011).
While the current study built on previous research by examining side effects for both 
prescribed and non-prescribed users, while also considering gender differences, the current 
study was limited due to reliance on self-report measures, which may have resulted in an 
underreporting of non-prescribed use and side effects. Additionally, we were unable to 
collect information on differences in dosages or specific medications taken, as many non-
prescribed users did not know this information.
Despite these limitations, the current study suggests some implications for strategies useful 
for preventing non-prescribed use on college campuses. Since non-prescribed users are not 
experiencing side effects as adverse, other ways of intervening and discouraging non-
prescribed use should be examined (e.g., publicizing the negative health consequences of 
use). In addition, future work should examine the possibility that dosage of psychostimulants 
should be adjusted based on sex in order to mitigate gender differences in side effects.
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Table 1
Demographics
N (%)
Sex
  Male 1448 (53.3)
  Female 1268 (46.7)
Age [M (SD)] 19.43 (1.7)
Race
  White 2269 (83.5)
  African American 228 (8.4)
Student Classification
  Freshman 1239 (45.6)
  Sophomore 796 (29.3)
  Junior 480 (17.7)
  Senior 199 (7.3)
Diagnosed with ADHD? 310 (11.4)
Taking prescribed ADHD meds? 197 (7.3)
Ever took non-prescribed ADHD meds? 826 (30.4)
Note. N= 2716.
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Table 2
Significant Differences in Side Effects Based on Prescribed vs. Non-prescribed Use
M (SD)
Prescribed
n=193
Non-prescribed
n=819 p
Side effects
  Loss of sex drive 1.93 (1.07) 1.65 (1.06)
.001**
  Loss of appetite 3.78 (1.08) 3.59 (1.41) .07
  Depression 2.29 (1.06) 1.59 (.99)
.00**
  Dry mouth 2.97 (1.37) 2.72 (1.53)
.04*
  Diarrhea 1.83 (1.10) 1.52 (.94)
.00**
  Dizziness 2 (.97) 1.64 (.97)
.00**
  Headaches 2.28 (1.09) 1.85 (1.12)
.00**
  Heartburn 1.6 (.84) 1.31 (.71)
.00**
  Irritability 2.63 (1.19) 1.85 (1.19)
.00**
  Nausea 1.76 (.93) 1.59 (.97)
.03*
  Insomnia 3.27 (1.07) 3.45 (1.44) .10
  Sweating 2.53 (1.24) 2.25 (1.39)
.01*
  Increased heart rate 3.01 (1.21) 2.89 (1.46) .32
  Nervousness 2.59 (1.18) 2.03 (1.27)
.00**
  Paranoia 2.09 (1.18) 1.71 (1.10)
.00**
Note. 1=Never. 5=Always.
*p < .05,
**p < .01.
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Table 3
Gender Differences in Side Effects: Prescribed Users
M (SD)
Male
n=103
Female
n=90 p
Side effect
  Loss of sex drive 1.96 (1.11) 1.89 (1.02) .64
  Loss of appetite 3.61 (1.15) 3.98 (.95)
.02*
  Depression 2.16 (1.07) 2.44 (1.04) .06
  Dry mouth 2.87 (1.31) 3.09 (1.43) .28
  Diarrhea 1.80 (1.09) 1.87 (1.12) .69
  Dizziness 1.84 (.91) 2.18 (1.02)
.02*
  Headaches 1.97 (.97) 2.64 (1.12)
.00**
  Heartburn 1.63 (.86) 1.57 (.82) .64
  Irritability 2.46 (1.09) 2.81 (1.28) .04
  Nausea 1.61 (.81) 1.92 (1.04)
.02*
  Insomnia 3.16 (1.06) 3.40 (1.07) .12
  Sweating 2.63 (1.24) 2.41 (1.24) .21
  Increased heart rate 2.97 (1.19) 3.04 (1.23) .68
  Nervousness 2.42 (1.10) 2.77 (1.24)
.04*
  Paranoia 2.02 (1.14) 2.16 (1.22) .39
Note. 1=Never. 5=Always.
*p < .05.
**p < .01.
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Table 4
Gender Differences in Side Effects: Non-Prescribed Users
M (SD)
Male
n=459
Female
n=360 p
Side effects
  Loss of sex drive 1.81 (1.15) 1.44 (.91)
.00**
  Loss of appetite 3.55 (1.40) 3.63 (1.41) .42
  Depression 1.61 (.99) 1.56 (.98) .52
  Dry mouth 2.76 (1.48) 2.68 (1.59) .50
  Diarrhea 1.56 (.93) 1.48 (.96) .22
  Dizziness 1.54 (.86) 1.76 (1.08)
.002**
  Headaches 1.73 (1.01) 2.01 (1.24)
.001**
  Heartburn 1.34 (.76) 1.27 (.64) .14
  Irritability 1.84 (1.13) 1.87 (1.25) .68
  Nausea 1.51 (.86) 1.68 (1.09)
.02*
  Insomnia 3.35 (1.41) 3.57 (1.47)
.03*
  Sweating 2.35 (1.42) 2.12 (1.33)
.02*
  Increased heart rate 2.81 (1.42) 3.00 (1.50) .06
  Nervousness 1.88 (1.16) 2.22 (1.37)
.00**
  Paranoia 1.64 (1.03) 1.80 (1.17)
.04*
Note. 1=Never. 5=Always.
*p < .05.
**p < .01.
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